Literature DB >> 22436454

Alphavirus replicon vaccines.

Ryan L Vander Veen1, D L Hank Harris, Kurt I Kamrud.   

Abstract

The alphavirus replicon technology has been utilized for many years to develop vaccines for both veterinary and human applications. Many developments have been made to the replicon platform recently, resulting in improved safety and efficacy of replicon particle (RP) vaccines. This review provides a broad overview of the replicon technology and safety features of the system and discusses the current literature on RP and replicon-based vaccines.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22436454     DOI： 10.1017/S1466252312000011

Source DB:  PubMed          Journal:  Anim Health Res Rev        ISSN： 1466-2523            Impact factor:   2.615


  20 in total

1.  Semliki Forest Virus replicon particles production in serum-free medium BHK-21 cell cultures and their use to express different proteins.

Authors:  Sandra Fernanda Suárez-Patiño; Thaissa Consoni Bernardino; Eutimio Gustavo Fernández Núñez; Renato Mancini Astray; Carlos Augusto Pereira; Hugo R Soares; Ana S Coroadinha; Soraia Attie Calil Jorge
Journal:  Cytotechnology       Date:  2019-08-17       Impact factor: 2.058

2.  Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines.

Authors:  Yun-Zhou Yu; Yao Ma; Wen-Hui Xu; Shuang Wang; Zhi-Wei Sun
Journal:  Med Microbiol Immunol       Date:  2014-09-30       Impact factor: 3.402

Review 3.  Vaccines against respiratory viral pathogens for use in neonates: opportunities and challenges.

Authors:  Martha A Alexander-Miller
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

Review 4.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

5.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

6.  Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.

Authors:  Eugenio J Abente; Daniela S Rajao; Jefferson Santos; Bryan S Kaplan; Tracy L Nicholson; Susan L Brockmeier; Phillip C Gauger; Daniel R Perez; Amy L Vincent
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

Review 7.  Novel vaccine strategies against emerging viruses.

Authors:  Adolfo García-Sastre; Ignacio Mena
Journal:  Curr Opin Virol       Date:  2013-03-07       Impact factor: 7.090

Review 8.  Advanced vaccine candidates for Lassa fever.

Authors:  Igor S Lukashevich
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

9.  Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle.

Authors:  John Dustin Loy; Jill Gander; Mark Mogler; Ryan Vander Veen; Julia Ridpath; Delbert Hank Harris; Kurt Kamrud
Journal:  Virol J       Date:  2013-01-28       Impact factor: 4.099

Review 10.  Optimal Use of Vaccines for Control of Influenza A Virus in Swine.

Authors:  Matthew R Sandbulte; Anna R Spickler; Pamela K Zaabel; James A Roth
Journal:  Vaccines (Basel)       Date:  2015-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.